Licensing Agreements

Drug Development Patent Litigation Sanofi Oncology Cancer Drugs Cancer Treatment Market Strategy Arrowhead Pharmaceuticals Partnerships Collaborations Product Development Obesity Medications Collaboration Deals Technology Transfer

5 ARTICLES

2w ago

Nanexa Licenses PharmaShell to Novo Nordisk in Deal Worth Up to €1.17 Billion

The agreement gives Novo Nordisk exclusive rights for up to five programs to develop monthly or quarterly long‑acting injectables and assigns development and commercialization responsibility to Novo Nordisk.

5 ARTICLES

last mo.

SK Biopharmaceuticals Licenses Biohaven’s Opakalim in Deal Worth Up to $795 Million

5 ARTICLES

2mo ago

Novartis Licenses Arrowhead’s RNAi Parkinson’s Drug in Deal Worth Up to $2.2 Billion

Licensing Agreements

Nanexa Licenses PharmaShell to Novo Nordisk in Deal Worth Up to €1.17 Billion

SK Biopharmaceuticals Licenses Biohaven’s Opakalim in Deal Worth Up to $795 Million

AstraZeneca Licenses Global Rights to Zegfrovy From Dizal

Bristol Myers and Hengrui Ink Up to $15.2 Billion Drug Discovery Alliance

Lilly Licenses MeiraGTx Eye Gene Therapy in Deal Worth Up to $475 Million

Novartis Licenses Arrowhead’s RNAi Parkinson’s Drug in Deal Worth Up to $2.2 Billion